Print

VivaMab and ADC Therapeutics Announce Antibody Licensing Deal for Novel ADC Candidate to Target Hematologic Cancers  
6/24/2013 11:05:43 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO & LAUSANNE, Switzerland--(BUSINESS WIRE)--VivaMab, a therapeutic development division of BioAtla LLC, and ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates ('ADCs'), today announced a licensing deal for a novel antibody against an undisclosed hematological cancer target. Under the terms of the deal, ADC Therapeutics has licensed a VivaMab antibody (VM101) produced using BioAtla’s Express Humanization™, Comprehensive Positional Evolution™, Combinatorial Protein Synthesis™ affinity and functional maturation technology platforms. VM101 has been combined with a third-generation cytotoxic pyrrolobenzodiazepine (PBD)-based warhead and proprietary linker technology to form a novel ADC, which has already been shown to have powerful in vivo efficacy in established models for normally intractable hematological cancer indications.

Help employers find you! Check out all the jobs and post your resume.

//-->